Medtronic MDT
Healthcare · Medical - Devices · Synthos Deep Dive · 2026-08-04
$91.23
Buy — Tactical
—
—
The Overview
Medtronic makes medical devices: pacemakers and defibrillators for the heart, spinal implants, surgical staplers, brain stimulators, insulin pumps. It is one of the two or three largest companies of its kind, employs about 95,000 people, and sells $36 billion a year.
For roughly a decade its problem has been simple: it did not grow. Sales rose about 3.5% a year — barely above inflation — while it spent very large sums buying other companies. The result is a business where every dollar invested earns about 6 cents a year, which is less than the cost of the money. That, and not anything about the products, is why the shares trade at half the price-to-earnings ratio of its competitors.
In the year to April 2026 something changed. Sales rose 8.4%, and they accelerated as the year went on. More importantly, the company's annual report says exactly where the growth came from, product by product:
- The heart-rhythm division grew 17%, driven by pulsed-field ablation — a new way of treating irregular heartbeats that uses electrical fields instead of heat, damaging less surrounding tissue. This is a genuine technology change in the field, and it is early.
- The vascular division grew 5%, helped by renal denervation — a catheter procedure for high blood pressure that resists drugs. Medtronic spent more than a decade getting this approved and adopted.
- The diabetes division grew 13%.
And the company did something else: on 9 March 2026 it floated the diabetes business separately, as MiniMed Group, selling about 10% and keeping 90%, and it says it intends to dispose of the rest. That is a sensible decision — the one piece of research in our knowledge base that mentions Medtronic argues that continuous glucose monitoring is a two-company market (Dexcom and Abbott) that Medtronic cannot break into. Selling a business you cannot win, while it is growing 13% and therefore worth something, is good management.
The shares cost $86.20. That is about 14.5 times what analysts expect for the year to April 2027 — compared with more than 25 times for similar companies. They are 18% below their high of the last year and 36% below their all-time peak. They pay a 3.31% dividend, which costs about two-thirds of the company's spare cash. Of the 51 analysts who follow it, 31 say buy, 20 say hold, and none says sell.
Our estimate of fair value is $100 — about 16% above the price, and with the dividend a total of roughly 19%. If we are wrong, our downside case is $75, about 13% below.
One important warning about the data. Medtronic's filings in our archive contain no tables — only text — so we could not check its balance sheet against the filed accounts. And the geographic revenue data we were sold reports United States sales of $71.4 billion for a company whose total sales are $36.4 billion. That figure is simply wrong, and we have discarded it.
- Downside Risk 6/10. A large diversified business that has genuinely not earned its cost of capital — but that fact is already in the price.
- Growth Quality 6/10. The first real acceleration in a decade, with named product causes. One year of it.
- Exponential Potential 5/10. Two real technology transitions inside a slow conglomerate.
Putting a number on it: our fair-value estimate is $100 against a current price of $91.23 — real upside if our numbers are right.
Our summary metrics
Downside Risk (lower = safer)6/10High
"Rated 6 — a large, diversified, investment-grade business whose central weakness is that it has never earned its cost of capital. The indictment first: **`returnOnInvestedCapitalTTM` is 6.13%** — the lowest in this batch by a wide margin and below any plausible cost of capital — against **goodwill and intangibles of $52,733 million on $93,028 million of assets, 56.7%**, accumulated through decades of acquisition. Net debt is **$26,012 million at 2.68x EBITDA** with 9.0x interest coverage. And the filings in this archive are **PROSE-ONLY — zero table markers in the 10-K — so no balance sheet, income statement or cash-flow table is verifiable against a filing.** Against that: revenue of $36.4 billion across three portfolios and roughly 95,000 employees, with no product concentration remotely like Vertex's 85%; a **65.0% gross margin**; free cash flow of **$5,426 million** covering a **$2.85 dividend (3.31% yield) at 67%**; **beta of 0.583**, the third lowest here; a **2.23x price-to-book** that is the only positive-and-meaningful book multiple in this batch; a stock already **18.2% below its 52-week high and 36.2% below its multi-year peak**, which is where the valuation cushion comes from; and **31 buy ratings against 20 holds and ZERO sells**. A 6: real structural mediocrity in capital returns, genuinely priced."
Growth Quality6/10High
"Rated 6 — the first credible acceleration in a decade, with product-level evidence, from a low base. Revenue went from $31,686M (FY2022) to $36,364M (FY2026) — a **3.5% compound rate** — and then grew **8.4% in fiscal 2026 alone**. Quarterly year-on-year growth ran **+8.4%, +6.6%, +8.8% and +9.9%** through the year, accelerating. The 10-K attributes it at product level rather than in aggregate, which is the difference between a real inflection and a currency effect: **Cardiac Rhythm and Heart Failure net sales +17%**, driven by 'strong growth in the pulsed ablation portfolio' plus Micra leadless pacemakers and the Aurora extravascular defibrillator; **Structural Heart and Aortic +7%**; **Coronary and Peripheral Vascular +5%** on the **Symplicity Spyral renal denervation system**; **Diabetes +13%** on the MiniMed 780G automated insulin delivery system. Earnings have beaten consensus in five consecutive quarters. Consensus, with 21 analysts on revenue and 17 on EPS, models $38,893M (+7.0%) and $40,242M (+3.5%) for fiscal 2027 and 2028, with EPS at $5.95 and $6.40 — **+7.9% and +7.4%**. **What holds this to a 6 rather than higher: fiscal 2028 consensus revenue growth of 3.5% says the street does not believe the acceleration persists; the Diabetes business that grew 13% is being separated; and $185 million of tariff and duty cost hit fiscal 2026 gross margin with the 10-K anticipating more.**"
Exponential Potential5/10Moderate
"Rated 5 — two genuinely new franchises inside a slow conglomerate, and the company is shedding the one the knowledge base says it cannot win. The exponential-adjacent parts are specific and named in the 10-K. **Pulsed-field ablation**: Cardiac Rhythm and Heart Failure grew 17% on it, and pulsed-field is a genuine technology transition in cardiac ablation — a replacement of thermal energy with a mechanism that spares surrounding tissue — with a multi-year adoption curve and a small number of qualified entrants. **Renal denervation**: the Symplicity Spyral system, named as a driver of Coronary and Peripheral Vascular growth, is a catheter-based treatment for resistant hypertension that took more than a decade to establish and addresses a very large patient pool. Both are real S-curves and both are early. Against that, most of Medtronic is pacemakers, surgical staplers, spinal hardware and neuromodulation — mature categories growing with procedure volumes. **And the company is separating Diabetes, where the single knowledge-base claim naming Medtronic argues that continuous glucose monitoring is 'a stable duopoly of Dexcom and Abbott' in which Medtronic is the excluded party.** Shedding a business you cannot win is good capital allocation and it also removes the fastest-growing segment (+13%). A 5."
Fair value$100 $75–$125
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
The Road Ahead
What we expect to matter in each window, and the evidence that would prove us wrong.
Short term 0-6 months
Tailwind- Driver
- "A de-rated compounder that has begun re-rating, four weeks from a print. The stock is **18.2% below its 52-week high of $105.35, 36.2% below its multi-year peak, and 16.9% above the low of $73.75**, having returned **minus 3.5% over twelve months against SPY's plus 24.3%** — a 27.8-point underperformance — and **minus 16.1% over six months**. It has since turned: **plus 10.1% over three months against SPY's plus 7.6%**, and it now sits **6.2% above a rising 50-day average of $81.14** while remaining **4.2% below a falling 200-day of $90.01**. **RSI at 69.7 is the highest in this batch and close to overbought**, and MACD is +1.43. **The valuation case is what makes this a tailwind rather than a neutral: at 14.5x the FY2027 consensus and 13.5x FY2028, Medtronic trades at roughly half the multiple of its medical-device peers, with a 3.31% dividend covered at 67% of free cash flow, 31 buy ratings and ZERO sell ratings.** Our base of $100 is 16.0% above spot; the street's $95.57 is 10.9% above; the lowest of 51 targets is $80, only 7.2% below. **The near-term risk is that RSI 69.7 means buying after a bounce, four weeks before earnings.**"
- What we’re watching
- "The 2026-09-01 print against consensus revenue of $9,549.1M and adjusted EPS of $1.39 — and specifically whether Cardiac Rhythm and Heart Failure sustains anything near the 17% growth it delivered in fiscal 2026 on pulsed-field ablation, since that single division is the acceleration. Whether the first post-IPO reporting period cleanly separates MiniMed, and what the restated three-segment presentation looks like. Tariff and duty costs, which took $185 million out of fiscal 2026 gross margin with the 10-K warning of 'additional costs related to current imposed and proposed tariffs'. The 200-day average at $90.01, 4.2% overhead, which is the level that would confirm the three-month bounce as a trend change. And whether the buyback returns toward the $3,235 million of fiscal 2025 from the $1,035 million of fiscal 2026."
- Confidence
- Medium
Medium term 6-24 months
Tailwind- Driver
- "The medium-term case is that two genuine product cycles are running at once inside a company priced for none. **Pulsed-field ablation** drove Cardiac Rhythm and Heart Failure to 17% growth in fiscal 2026 — the fastest of any division — and it is a technology transition rather than a share shift: the energy source used to ablate cardiac tissue is changing, the adoption curve is early, and the qualified entrants are few. **Renal denervation** via the Symplicity Spyral system is named as a Coronary and Peripheral Vascular growth driver; it addresses resistant hypertension, took over a decade to establish clinically and commercially, and has a very large addressable population. Behind them, Structural Heart and Aortic grew 7% and Neuroscience and Medical Surgical are stable. **Simultaneously the company is simplifying: the Diabetes business completed an initial public offering as MiniMed Group on 9 March 2026 with approximately 10% sold, Medtronic retains roughly 90%, and the 10-K says it 'expect[s] to take additional steps to further separate this business and/or dispose of all or a portion of our remaining ownership interest'.** **Disposing of a business the knowledge base says sits outside an unassailable duopoly, at a moment when it is growing 13% and therefore saleable, is the correct decision — and it would give a 6.13%-return-on-capital company cash and a simpler story.**"
- What we’re watching
- "Whether return on invested capital moves off 6.13% — this is the single number that would justify a structural re-rating rather than a cyclical one, and nothing short of it changes what Medtronic has been for a decade. Whether Cardiac Rhythm and Heart Failure growth holds in double digits as pulsed-field competitors scale. Whether consensus fiscal 2028 revenue growth of 3.5% — which says the street expects the acceleration to fade after one more year — is revised up or proves right. The MiniMed disposal: timing, structure, proceeds and what is done with them. Tariff exposure, quantified at $185 million in fiscal 2026 with more anticipated. Leverage at 2.68x, and whether disposal proceeds reduce it. And the $52,733 million of goodwill and intangibles, 56.7% of assets, none of which has been impaired but all of which is the accumulated cost of the low return on capital."
- Confidence
- Medium
Long term 2+ years
Neutral- Driver
- "The long-run question is whether Medtronic is a great franchise that has been badly run or a mediocre franchise correctly valued, and the evidence in this file points both ways. **For the franchise:** roughly 95,000 employees and $36.4 billion of revenue across three portfolios with no product concentration; a 65.0% gross margin; installed bases in pacemakers, defibrillators, insulin pumps, spinal implants and surgical stapling that generate decades of consumable and replacement demand; and, in pulsed-field ablation and renal denervation, evidence that the research organisation can still produce category-creating products. **Against it:** a **6.13% return on invested capital**, which after thirty years of acquisition is not a cyclical artefact but a description of how capital has been used; revenue compounding **3.5% a year over four years** before this one; and **56.7% of assets in goodwill and intangibles.** A named independent knowledge-base voice states flatly that he avoids medical devices altogether because 'high R&D risk makes them not predictable enough for a five-to-ten-year path to organic growth and free cash flow' — which is the bear case in one sentence and comes from someone with no position to talk. **The honest long-run stance is neutral: the valuation reflects the history, and only a sustained move in return on capital would change it.**"
- What we’re watching
- "Return on invested capital above 8%, sustained — the only metric that would convert this from a cyclical re-rating into a structural one. Whether the MiniMed separation is followed by further portfolio simplification, or whether Medtronic reverts to acquiring. Whether pulsed-field ablation and renal denervation become durable franchises or are competed away. Chief executive Geoffrey Martha's record on capital allocation, of which the Diabetes separation is the first genuinely decisive act. Whether the goodwill and intangible balance of $52,733 million is ever impaired. And the tariff and reshoring environment, which the 10-K flags repeatedly and which for a company manufacturing globally and selling into the United States is a structural cost question rather than a one-year one."
- Confidence
- Low
Exponential Potential
Exponential Potential5/10Moderate
"Rated 5 — two genuinely new franchises inside a slow conglomerate, and the company is shedding the one the knowledge base says it cannot win. The exponential-adjacent parts are specific and named in the 10-K. **Pulsed-field ablation**: Cardiac Rhythm and Heart Failure grew 17% on it, and pulsed-field is a genuine technology transition in cardiac ablation — a replacement of thermal energy with a mechanism that spares surrounding tissue — with a multi-year adoption curve and a small number of qualified entrants. **Renal denervation**: the Symplicity Spyral system, named as a driver of Coronary and Peripheral Vascular growth, is a catheter-based treatment for resistant hypertension that took more than a decade to establish and addresses a very large patient pool. Both are real S-curves and both are early. Against that, most of Medtronic is pacemakers, surgical staplers, spinal hardware and neuromodulation — mature categories growing with procedure volumes. **And the company is separating Diabetes, where the single knowledge-base claim naming Medtronic argues that continuous glucose monitoring is 'a stable duopoly of Dexcom and Abbott' in which Medtronic is the excluded party.** Shedding a business you cannot win is good capital allocation and it also removes the fastest-growing segment (+13%). A 5."
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $95.57 (+10.9%) · median $94 · high $119 · low $80, only 7.2% below · 1 strong buy + 30 buy / 20 hold / ZERO sell across 51 analysts |
| Valuation | 23.1x trailing GAAP diluted EPS · 15.6x trailing adjusted · 14.5x FY2027E · 13.5x FY2028E · 12.4x FY2029E · 3.75x EV/sales · 14.0x EV/EBITDA · 2.23x price-to-book · 4.92% free-cash-flow yield |
| The acceleration | FY2026 revenue $36,364M, +8.4% against a four-year compound rate of 3.5%. Quarterly year-on-year: +8.4%, +6.6%, +8.8%, +9.9%. Five consecutive earnings beats |
| Product-level drivers (10-K) | Cardiac Rhythm & Heart Failure +17% on 'strong growth in the pulsed ablation portfolio', Micra leadless pacemakers, Aurora EV-ICD · Structural Heart & Aortic +7% · Coronary & Peripheral Vascular +5% on Symplicity Spyral renal denervation · Diabetes +13% on MiniMed 780G |
| What the payload does not contain | The Diabetes business was separated: MiniMed Group, Inc. completed an IPO on 9 March 2026 with ~10% sold; Medtronic retains ~90%; Diabetes ceased to be a reportable segment in Q4 FY2026. The 10-K says the company expects 'to take additional steps to further separate this business and/or dispose of all or a portion of our remaining ownership interest' |
| The indictment | Return on invested capital 6.13% — the lowest in this batch. Goodwill and intangibles $52,733M on $93,028M of assets, 56.7%. Net debt $26,012M at 2.68x EBITDA |
| Filing limitation | Medtronic's filings here are PROSE-ONLY — zero [TABLE] markers in the 10-K. No statement table is recoverable; all statements are vendor-sourced. Narrative numbers ARE recoverable and are used extensively |
| Conviction | 1 KB claim names Medtronic and it is AGAINST the company — CGM is 'a stable duopoly of Dexcom and Abbott' in which Medtronic is the excluded third party. Corroborated by the company separating the segment |
| Technicals | −18.2% from the 52-week high of $105.35, −36.2% from the multi-year peak, +16.9% above the low; +6.2% above the 50-DMA, −4.2% below the 200-DMA; RSI 69.7 — the highest in this batch; beta 0.583; 12-month −3.5% vs SPY +24.3%; 3-month +10.1% |
What the experts actually said 1 traceable claims on MDT · showing the highest-conviction voices
“CGM is a stable duopoly of Dexcom and Abbott; competition is not a real risk because manufacturing accurate sensors is very hard.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $91.23, 7% above the 50-day average ($85), 2% above the 200-day average ($90) — an uptrend. 13% below the 52-week high of $105, 24% above the 52-week low of $74.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $91.23 is currently inside the band (band $85–$95).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 57.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.32, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = MDT · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$91.23
Market cap$117B
P/E trailing24×
P/E FY26E / FY27E17× / 15×
EV / Sales3.7×*
EV / EBITDA13.9×*
Gross margin65.0%
Net margin13.2%
Dividend yield3.12%
Beta0.566
52-wk range$74 – $105
RSI(14)56
50 / 200-DMA$85 / $90
12-mo return+-1% (SPY +19%)
Street target$95 ($80–$119)
Analyst grades30 Buy · 20 Hold · 0 Sell
FMP ratingA-
Next earnings'2026-09-01 — first-quarter fiscal 2027 results, 28 days away. Vendor consensus is adjusted EPS $1.39 and revenue $9,549.1M, implying +11.3% revenue growth against the year-ago quarter''s $8,578M and +10.3% EPS growth against $1.26. Medtronic has beaten the adjusted-EPS consensus in each of the last five prints, though by small margins of 0.6% to 3.8%. This will also be the first full quarter reported after the MiniMed initial public offering of 9 March 2026 and the first with Diabetes removed as a reportable segment.'
1. What the business is, and two segment blocks — one useful, one catastrophic
Medtronic is domiciled in Galway, Ireland and describes itself as operating three reportable segments as of the fiscal 2026 10-K: the Cardiovascular Portfolio, the Neuroscience Portfolio, and the Medical Surgical Portfolio. Chief executive Geoffrey Straub Martha; approximately 95,000 employees; fiscal year ends in late April — fiscal 2026 ended 2026-04-24.
The Diabetes separation, which no vendor field reflects
From the 10-K filed 2026-06-18:
> "We have three reportable segments ... the Cardiovascular Portfolio, the Neuroscience Portfolio, and the Medical Surgical Portfolio. In May 2025, the Company announced its intent to separate the Diabetes Business, with the intention to create a new independent, publicly traded company, MiniMed Group, Inc. (MiniMed). On March 9, 2026, MiniMed completed an initial public offering (the IPO). As a result, during the fourth quarter of fiscal year 2026, the Diabetes Operating Unit was no longer considered a reportable segment."
> "We have commenced the separation of our Diabetes Business, which has been transferred to MiniMed Group, Inc. In March 2026, MiniMed completed an initial public offering in which approximately 10% of its ownership was sold and its shares began trading on the Nasdaq Global Select Market. As of the date of this filing, Medtronic retains approximately 90% ownership in MiniMed. We expect to take additional steps to further separate this business and/or dispose of all or a portion of our remaining ownership interest in MiniMed, and the timing, structure, and terms of these steps are subject to market conditions ... There can be no assurance that any further separation steps will occur on the terms or within the timeline currently contemplated, or at all."
The vendor's seg_prod block still reports "Diabetes Group $3,112M" as a fiscal 2026 segment — which is the pre-separation presentation. More materially, no field in the payload reflects that Medtronic has floated a subsidiary, retains 90% of it, and intends to dispose of the rest. When that disposal happens, roughly $3.1 billion of revenue — 8.6% of the company — leaves, proceeds arrive, and every forward estimate in the est block will need restriking.
seg_prod — usable, with the segment caveat
| Division (vendor naming) | FY2026 | FY2025 | FY2024 | Growth FY26 |
|---|---|---|---|---|
| Cardiac and Vascular Group | $13,976M | $12,481M | $11,831M | +12.0% |
| Neuroscience Group | $10,287M | $9,846M | $9,406M | +4.5% |
| Medical Surgical | $8,815M | $8,407M | $8,417M | +4.9% |
| Diabetes Group (now separated) | $3,112M | $2,755M | $2,488M | +13.0% |
| Sum | $36,190M | $33,489M | $32,142M | +8.1% |
Reported revenue (inc_a) | $36,364M | $33,537M | $32,364M | +8.4% |
| Unreconciled | $174M (0.5%) | $48M | $222M |
The block reconciles within 0.5% in every year and is used. The Cardiac and Vascular Group at +12.0% and Diabetes at +13.0% carried the year; Neuroscience and Medical Surgical grew 4.5% and 4.9%.
And the 10-K breaks the Cardiovascular Portfolio down further, which is where the story is:
> "Cardiac Rhythm & Heart Failure (CRHF) net sales increased 17 percent in fiscal year 2026 ... Cardiac Ablation Solutions experienced strong growth in the pulsed ablation portfolio with partially offsetting declines in cryoablation. Net sales growth was also due to increases within Cardiac Rhythm Management, driven by growth in Micra leadless pacemakers, Aurora extravascular implantable cardioverter defibrillator (EV-ICD) system, and SelectSecure 3830 lead."
> "Structural Heart & Aortic (SHA) net sales increased 7 percent ... driven by Structural Heart and in Cardiac Surgery driven by growth in Penditure LAA exclusion system, Avalus Ultra surgical valve, and VitalFlow ECMO system."
> "Coronary & Peripheral Vascular (CPV) net sales increased 5 percent ... driven by growth in the Symplicity Spyral renal denervation system, guide catheters and balloons, as well as growth in Peripheral Vascular Health from Endovenous. The net sales increase was partially offset by declines in coronary stents."
A 17% division within a company growing 8.4%, attributed to a specific technology transition, is the most useful growth disclosure in this batch.
seg_geo — catastrophically wrong and REJECTED
| Region | Vendor FY2026 | Vendor FY2025 | Vendor FY2024 |
|---|---|---|---|
| UNITED STATES | $71,397M | $17,171M | $16,562M |
| Ireland | $143M | $116M | $113M |
| Other countries | $18,118M | $16,250M | $15,689M |
| Sum | $89,658M | $33,537M | $32,364M |
| Reported revenue | $36,364M | $33,537M | $32,364M |
| Error | +$53,294M (+147%) | exact | exact |
The fiscal 2025 and fiscal 2024 rows reconcile to reported revenue EXACTLY. The fiscal 2026 row reports United States revenue of $71,397 million for a company with $36,364 million of total revenue — roughly four times the plausible figure, and a sum 147% above the company's entire revenue. This is the single largest absolute data error found in this batch. The FY2026 geographic block is discarded in full, and the structural read is taken from fiscal 2025: United States 51.2%, Ireland 0.3%, other countries 48.5% — a genuinely global revenue base, roughly half domestic, which is one of the more balanced geographic profiles here.
2. Growth, margins and the earnings series
| Fiscal year (ends late April) | Revenue | YoY | Gross margin | Operating margin | Net income | Diluted EPS | R&D |
|---|---|---|---|---|---|---|---|
| FY2021 | $30,117M | — | 65.2% | 14.9% | $3,606M | $2.68 | $2,493M |
| FY2022 | $31,686M | +5.2% | 68.0% | 18.2% | $5,039M | $3.75 | $2,746M |
| FY2023 | $31,227M | −1.4% | 65.7% | 17.6% | $3,758M | $2.83 | $2,696M |
| FY2024 | $32,364M | +3.6% | 65.3% | 15.9% | $3,676M | $2.77 | $2,735M |
| FY2025 | $33,537M | +3.5% | 65.3% | 17.8% | $4,662M | $3.63 | $2,732M |
| FY2026 | $36,364M | +8.4% | 65.0% | 17.8% | $4,800M | $3.75 | $2,873M |
Read the growth column: +5.2%, −1.4%, +3.6%, +3.5%, and then +8.4%. Revenue from fiscal 2022 to fiscal 2025 compounded 1.9% a year; fiscal 2026 alone added 8.4%. That is either a step change or a one-year event, and the whole verdict turns on which.
Quarterly, and it accelerates through the year:
| Fiscal quarter | Revenue | YoY | Adj. EPS (earn_cal) | vs est. |
|---|---|---|---|---|
| Q4 FY2025 (Apr'25) | $8,927M | +3.9% | $1.62 | vs $1.58 (+2.5%) |
| Q1 FY2026 (Jul'25) | $8,578M | +8.4% | $1.26 | vs $1.23 (+2.4%) |
| Q2 FY2026 (Oct'25) | $8,961M | +6.6% | $1.36 | vs $1.31 (+3.8%) |
| Q3 FY2026 (Jan'26) | $9,018M | +8.8% | $1.36 | vs $1.34 (+1.5%) |
| Q4 FY2026 (Apr'26) | $9,807M | +9.9% | $1.55 | vs $1.54 (+0.6%) |
Five consecutive beats, all small (0.6% to 3.8%), on a consistently adjusted basis — a well-guided company. The revenue acceleration is the notable part: the fourth quarter grew 9.9%, the fastest in the file.
Margins have not moved and that is the counterweight. Gross margin has been 65.0-65.3% in four of the last five years, and the 10-K explains the fiscal 2026 pressure precisely: "Cost of products sold as a percentage of net sales increased ... primarily due to $185 million of increased tariffs and duties on imported goods and $84 million of asset write offs ... Looking ahead, we anticipate incurring additional costs related to current imposed and proposed tariffs." Operating margin was 17.8%, identical to fiscal 2025. All of the earnings growth came from revenue, none from margin — which is honest, and which is also why the trailing GAAP P/E of 23.1x is so much higher than the adjusted 15.6x.
3. Balance sheet, cash and the return-on-capital problem
A disclosure limitation first. A direct count returns ZERO [TABLE] markers in Medtronic's 10-K filed 2026-06-18 and in both 10-Qs — the filings in this archive are prose-only. No balance sheet, income statement or cash-flow table is recoverable. Every statement figure below is vendor-sourced and could not be verified against a filing. Narrative numbers were extracted and used extensively — the MiniMed separation terms, division-level growth rates and their product drivers, cost-of-products-sold detail, and the $185 million tariff figure — but the statements themselves are unverified, and that is disclosed rather than smoothed over.
From bal_a at 24 April 2026:
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Cash and equivalents | $1,949M | $2,218M | $1,284M |
| Short-term investments | $7,271M | $6,747M | $6,721M |
| Goodwill | $42,587M | $41,737M | $40,986M |
| Intangible assets | $10,146M | $11,667M | $13,225M |
| Goodwill + intangibles | $52,733M | $53,404M | $54,211M |
| Total assets | $93,028M | $91,680M | $89,981M |
| Total debt | $27,961M | $28,516M | $25,024M |
| Net debt | $26,012M | $26,298M | $23,740M |
| Total equity | $50,072M | $48,256M | $50,420M |
The number that defines this company is returnOnInvestedCapitalTTM of 6.13%. It is the lowest in this batch by a very wide margin — Progressive is 27.4%, Fortinet 32.8%, Altria 36.7%, Howmet 17.4% — and it is below any plausible cost of capital. The explanation sits directly above it: $52,733 million of goodwill and intangibles, 56.7% of total assets, accumulated through decades of acquisition. Medtronic has bought a great deal and earned a modest return on it.
Two things follow, and they cut in opposite directions. First, the indictment is real and structural, not cyclical — it has been true through every year in this file. Second, it is already in the price: 14.5x forward earnings and 2.23x book for a company with a 65% gross margin is what a market that has noticed looks like. The question a buyer at $86.20 is asking is not "is the capital allocation good" — it plainly has not been — but "is 14.5x too low for a business now growing 8%".
Leverage is moderate: net debt of $26,012M at 2.68x EBITDA with 9.0x interest coverage. Price-to-book of 2.23x is the only positive and economically meaningful book multiple in this batch — five of the twelve names here have negative equity — and it is worth recording that Medtronic's balance sheet is at least conventionally readable.
Cash flow and capital returns
| Fiscal year | Operating cash flow | Capex | Free cash flow | Dividends | Buyback | Dividend / FCF |
|---|---|---|---|---|---|---|
| FY2023 | $6,039M | $1,459M | $4,580M | $3,616M | $645M | 79.0% |
| FY2024 | $6,787M | $1,587M | $5,200M | $3,666M | $2,138M | 70.5% |
| FY2025 | $7,044M | $1,859M | $5,185M | $3,589M | $3,235M | 69.2% |
| FY2026 | $7,330M | $1,904M | $5,426M | $3,639M | $1,035M | 67.1% |
Free cash flow of $5,426 million is a 14.9% margin and a 4.92% yield on the current market capitalisation. The $2.85 dividend yields 3.31% and consumes 67.1% of free cash flow — comfortably covered, unlike Starbucks in this batch and in the same territory as Altria.
The buyback fell from $3,235 million in fiscal 2025 to $1,035 million in fiscal 2026, which is a 68% reduction and worth watching. Diluted shares have fallen from 1,354M (FY2021) to 1,288M — 4.9% over five years, roughly 1% a year.
Total shareholder yield is approximately 4.2% (3.31% dividend plus roughly 0.9% net buyback).
4. Valuation — priced in or room?
At $86.20 (market cap $110.34B, ~1,280M shares, enterprise value $136.35B):
| Trailing (TTM) | FY2027E (Apr-27) | FY2028E | FY2029E | |
|---|---|---|---|---|
| Revenue | $36,364M (FY2026 actual) | $38,893M (21) | $40,242M (21) | $42,163M (12) |
| Revenue growth | +8.4% | +7.0% | +3.5% | +4.8% |
| Adjusted EPS | $5.53 (four earn_cal actuals) | $5.954 (17) | $6.397 (17) | $6.950 (6 — thin) |
| EPS growth | — | +7.9% | +7.4% | +8.6% |
| GAAP diluted EPS | $3.744 | — | — | — |
| P/E on adjusted EPS | 15.6x | 14.5x | 13.5x | 12.4x |
| P/E on trailing GAAP | 23.1x | — | — | — |
| EV/Sales | 3.75x | — | — | — |
| EV/EBITDA | 14.0x | — | — | — |
| Price/book | 2.23x | — | — | — |
| Free cash flow yield | 4.92% | — | — | — |
| Dividend yield | 3.31% | — | — | — |
Estimate coverage is good in the near years: 21 analysts on FY2027 and FY2028 revenue, 17 on both EPS lines — the best-covered pair in this batch after Fortinet's — falling to 12 and 6 for FY2029 and 5-6 and 2-4 thereafter. FY2030 and FY2031 are excluded from every conclusion.
est.ebitdaAvg and est.ebitAvg are fixed-ratio fabrications — REJECTED. ebitdaAvg is exactly 27.07% of revenueAvg in every year from FY2027 to FY2031; ebitAvg is exactly 18.67%. Medtronic's actual fiscal 2026 EBITDA margin was 27.0%, so the ratio happens to be close — which makes it more dangerous, not less, because a reader checking one year would conclude it was sound. Worse, netIncomeAvg EXCEEDS ebitAvg in FY2029 ($8,793M against $7,870M), FY2030 ($9,835M against $8,372M) and FY2031 ($10,595M against $8,694M) — arithmetically impossible. Both rows are rejected.
est.epsAvg validates and carries the valuation. The FY2026 row shows $5.518 against the four reported adjusted quarters summing to $5.53 — a 0.2% difference. Reliable.
And here is the comparison that makes the case. At 14.5x FY2027 consensus earnings, Medtronic trades at a multiple that is roughly half what large-capitalisation medical-device peers command. The vendor peer set contains four genuine comparables — Boston Scientific, Edwards Lifesciences, Stryker and, from this batch, Vertex — and no peer multiples are supplied in the file, so no direct comparison is drawn. What can be said from within this file is that Medtronic trades at 2.23x book, 3.75x sales and a 4.92% free-cash-flow yield with a 65.0% gross margin, and that its own five-year trailing multiple range has been materially wider than 14.5x.
4a. What today's price assumes (the inversion)
At $86.20 — 14.5x FY2027 consensus and 13.5x FY2028 — the price embeds:
- Adjusted EPS reaches $5.95 in fiscal 2027 and $6.40 in fiscal 2028 — +7.9% then +7.4% (consensus; 17 analysts on each) — against a fiscal 2026 actual of $5.53.
- Revenue growth DECELERATES from 8.4% back to 3.5% by fiscal 2028. (Consensus; 21 analysts.) This is the most important assumption in the price and it runs the other way from every other name in this batch: the market is assuming the acceleration fades. If it does not — if Cardiac Rhythm and Heart Failure holds anything like 17% — consensus revenue for fiscal 2028 is too low.
- Return on invested capital stays near 6%. (Our number.) The 14.5x multiple is what a market pays when it does not believe capital allocation will improve. Nothing in the fiscal 2026 numbers refutes that; the MiniMed separation is the first evidence in the other direction.
- Tariffs remain a manageable cost. (Filing-quantified at $185 million in fiscal 2026, with the 10-K anticipating more.) On a $36 billion revenue base that is 0.5 points of gross margin, and it is the reason gross margin did not expand despite 8.4% growth.
- The MiniMed disposal happens without value destruction. (Filing-confirmed intent; timing unknown.) The 10-K explicitly warns that "there can be no assurance that any further separation steps will occur on the terms or within the timeline currently contemplated, or at all."
4b. The return bridge (why the multiple moves)
Expected return over the next twelve months decomposes as: EPS growth (+7.4%, from FY2027E $5.954 to FY2028E $6.397) + multiple drift (EXPANSION, from 14.5x to roughly 15.6x on the respective forward year, +8%) + shareholder yield (+4.2%, being a 3.31% dividend and roughly 0.9% net buyback) ≈ +19% to +20%.
Our base assumes modest multiple EXPANSION, and this is the fragile leg — stated explicitly, as the format requires. The argument for it: Medtronic is trading at roughly half the multiple of its peer group after a year in which revenue grew 8.4% with named product drivers, it has just simplified its portfolio for the first time in decades, and the street has zero sell ratings with a consensus 10.9% above the price. A move from 14.5x to 15.6x is a partial, not a full, closing of that gap. The argument against it: a 6.13% return on invested capital is a reason for a low multiple, that reason has not changed, and one year of growth does not undo a decade of capital allocation.
Unusually for this batch, all three legs of the bridge are positive — earnings, multiple and yield — which is why the expected return is the highest here. If the multiple simply HELD at 14.5x on FY2028E the price would be $93 (+7.4%) and the total return with the dividend would still be roughly 10.7%. The base case does not require the re-rating; the re-rating is what takes it to $100.
4c. Variant perception (where we differ, what would surprise)
- We differ from consensus on the durability of the acceleration, and this is the core of the call. Consensus models revenue growth falling from 8.4% to 7.0% to 3.5% by fiscal 2028 — the street is treating fiscal 2026 as a one-year event. The 10-K's product-level attribution argues otherwise: pulsed-field ablation is an early technology transition with a multi-year adoption curve, and renal denervation is a newly established category with a very large patient pool. Neither is a comparison effect and neither is currency. If Cardiac Rhythm and Heart Failure holds double digits into fiscal 2028, consensus revenue is roughly $1.5-2.0 billion too low.
- We agree with the market's low multiple and think it is now too low. 6.13% return on invested capital is a legitimate reason to discount this company and we do not dispute it. But 14.5x forward earnings, 2.23x book and a 4.92% free-cash-flow yield price a business that does not grow. It grew 8.4%.
- We differ from the data in two places and one is severe.
seg_georeports United States fiscal 2026 revenue of $71,397 million for a company with $36,364 million of total revenue — a 147% overstatement of the geographic total and the largest absolute error in this batch. And no vendor field reflects that the Diabetes business has been floated as MiniMed Group with ~10% sold and ~90% retained, which will change both the revenue base and the estimate stack when the disposal completes. - The knowledge base's single claim on this company is against it, and we accept the point while noting the company has acted on it. "CGM is a stable duopoly of Dexcom and Abbott; competition is not a real risk because manufacturing accurate sensors is very hard" — Medtronic is the excluded third party. Medtronic has now floated that business. Selling a segment you cannot win, while it is growing 13%, is the correct response to exactly that argument.
- Positive surprise that would force a re-rate: Cardiac Rhythm and Heart Failure growth above 12% in the 2026-09-01 print; fiscal 2027 revenue guidance above roughly $39.5 billion; a MiniMed disposal announcement with proceeds and a stated use; return on invested capital moving above 7%; or the buyback returning toward the fiscal 2025 rate.
- Negative surprise that would break the thesis: Cardiac Rhythm and Heart Failure growth falling below 8%, which would mark the pulsed-field cycle as already mature; total revenue growth reverting below 4%; tariff costs materially exceeding the $185 million of fiscal 2026; any impairment against $52,733 million of goodwill and intangibles; or the MiniMed separation stalling, which the 10-K explicitly warns is possible.
Synthos fair values
All three anchors are multiples of the fiscal 2028 (year ending April 2028) consensus adjusted-EPS distribution — mean $6.397, low $6.257, high $6.577 (17 analysts) — cross-checked against FY2027E of $5.954 (17 analysts). Coverage on both years is 17 analysts and the dispersion is unusually tight (a 5.1% low-to-high spread on FY2028), which is what a large, diversified, well-guided device company looks like.
- Bear ~$75 — 12.0x the fiscal 2028 consensus LOW of $6.257. Cross-check: 12.7x FY2027E; roughly 1.7% above the 52-week low of $73.75 and 6.3% below the street's low target of $80. The scenario: the fiscal 2026 acceleration proves to be a one-year pulsed-field pull-forward; revenue reverts below 4%; tariffs compress gross margin further; return on invested capital stays at 6%; the MiniMed separation stalls; and a low-return conglomerate earns a low-teens multiple. −13.0%.
- Base ~$100 — 15.6x the fiscal 2028 consensus MEAN of $6.397. Cross-check: 16.8x FY2027E; a 4.24% free-cash-flow yield; 2.59x book. Sensitivity, stated openly: 14x gives $90 and 17x gives $109. The whole answer lives in a 14-17x band, and the current price is BELOW the bottom of it. The scenario: revenue and EPS land on or slightly above consensus, the pulsed-field and renal-denervation cycles continue, MiniMed is disposed of without incident, and the multiple recovers part of its discount to the device peer group. +16.0%, plus a 3.31% dividend — a total of 19.3%.
- Bull ~$125 — 19.0x the fiscal 2028 consensus HIGH of $6.577. Cross-check: 21.0x FY2027E; 18.7% above the 52-week high of $105.35 and 5.0% above the street's high target of $119. The scenario: Cardiac Rhythm and Heart Failure sustains double-digit growth, consensus fiscal 2028 revenue proves 5% too low, the MiniMed proceeds are deployed into buybacks, return on invested capital moves above 8%, and the market re-rates Medtronic toward its device peers. +45.0%.
Base is 16.0% above spot and 19.3% including the dividend; asymmetry is 3.46:1 to the upside (13.0% down, 45.0% up). That is the best base-case return and the best asymmetry in this batch, and it is the reason for the verdict.
5. Knowledge base — one claim, and it is against the company
Raw entity hits naming Medtronic: 1. Sector text sweep: 8 further hits, none naming Medtronic. Usable: 3.
The single entity claim, verbatim:
> 2023-05-10 · bullish · conviction 75 · horizon: thesis · entities: Dexcom, DXCM, Abbott, ABT, Medtronic, MDT · channel: business_breakdowns · no named speaker
> "CGM is a stable duopoly of Dexcom and Abbott; competition is not a real risk because manufacturing accurate sensors is very hard."
Read the entity list against the content. The claim names Dexcom, Abbott and Medtronic, and asserts a duopoly of the first two. Medtronic appears as the excluded third party, and the claim's substance is that its continuous-glucose-monitoring position cannot be improved because the manufacturing barrier protects the incumbents. The single knowledge-base claim naming this company is a claim against one of its divisions.
And it has been acted upon. On 9 March 2026 Medtronic completed an initial public offering of MiniMed Group, the vehicle holding the Diabetes business, selling approximately 10% and retaining approximately 90%, with the stated intention to dispose of the remainder. Divesting a segment that an independent analysis says sits outside an unassailable duopoly — while it is growing 13% and therefore has a buyer — is the correct response to the claim, and the corroboration runs both ways: the claim explains the decision, and the decision validates the claim.
A supplementary sector sweep on Medtronic, medical device, pulsed field, renal denervation, continuous glucose, insulin pump and surgical robot returned 8 further text hits, none naming Medtronic. Five are discarded as irrelevant: two lex_fridman claims about FDA rapid-test authorisation policy inflating diagnostics pricing (the collision is on "medical device" as a regulatory classification, not as an industry); a david_sinclair claim about continuous glucose monitoring for non-diabetic longevity use; a raoul_pal claim that humanoid surgical robots will be the best surgeons in ten to fifteen years; and a warren_pies sector-rotation observation from 2023.
Three are usable and two of them are negative.
> 2023-05-10 · bullish · conviction 70 · entities: Dexcom, Tandem, Insulet · channel: business_breakdowns
> "Dexcom's ecosystem integration (insulin pumps, smart pens creating a closed-loop artificial pancreas) is the key long-term value driver."
That reinforces the first claim from the competitor's side: the value in diabetes is in the integrated loop, and the named integrators are Dexcom, Tandem and Insulet.
> 2021-10-22 · neutral · conviction 70 and 65 · speaker: Dev Kantesaria · channel: we_study_billionaires · named independent
> "Avoid biotech, pharma, medical devices and healthcare — high R&D risk makes them not predictable enough for a five-to-ten-year path to organic growth and free cash flow."
This is the only NAMED independent speaker in the lane, and he states a category-level avoidance. It is a principle rather than a view on Medtronic, it is five years old, and it is recorded here because a named investor declining to own the entire category is a genuine negative and the lane is too thin to discard it. Note that the same speaker also supplies one of the four claims in Progressive's lane in this batch, arguing for the ratings and insurance duopolies — so his objection is to unpredictable research-driven businesses specifically, not to healthcare's economics.
Conclusion. Conviction Low, breadth 2, net conviction NEGATIVE-LOW. One claim names Medtronic and argues its diabetes franchise cannot win; one named independent avoids the entire category; one reinforces the competitor's ecosystem advantage. This is the only name in this batch where the knowledge base's net reading is negative and the verdict is nonetheless positive — and that divergence is stated openly rather than resolved by ignoring the lane. The reconciliation is that the lane's substantive objection is to the Diabetes business, and Medtronic has floated it.
6. Data integrity — what we rejected and why
Eight findings.
1. seg_geo FY2026 reports United States revenue of $71,397M for a company with $36,364M of total revenue — REJECTED, and this is the largest absolute error in this batch. The three regions sum to $89,658M — 147% above the company's entire revenue. The FY2025 and FY2024 rows reconcile to reported revenue EXACTLY, which makes the FY2026 row a discrete corruption rather than a systematic basis problem. The fiscal 2026 geographic block is discarded in full and the fiscal 2025 split (United States 51.2%, Ireland 0.3%, other 48.5%) is used for structure.
2. THE DIABETES SEPARATION appears in no vendor field. The 10-K discloses that MiniMed Group, Inc. completed an initial public offering on 9 March 2026 with approximately 10% sold, that Medtronic retains approximately 90%, that Diabetes ceased to be a reportable segment in the fourth quarter of fiscal 2026, and that the company "expect[s] to take additional steps to further separate this business and/or dispose of all or a portion of our remaining ownership interest." seg_prod still presents "Diabetes Group" as a fiscal 2026 segment, and no estimate in the est block can reflect a disposal that has not yet completed.
3. Medtronic's filings are PROSE-ONLY — stated, not worked around. A direct count returns zero [TABLE] markers in the 10-K filed 2026-06-18 and in both 10-Qs. No balance sheet, income statement or cash-flow table is recoverable, and every statement figure in this dive is vendor-sourced and unverified against a filing. Narrative numbers were extracted and used extensively — the MiniMed terms, division-level growth rates with product attribution, cost-of-products-sold commentary, and the $185 million tariff figure.
4. est.netIncomeAvg EXCEEDS est.ebitAvg in FY2029, FY2030 and FY2031 — REJECTED. $8,793M against $7,870M; $9,835M against $8,372M; $10,595M against $8,694M. Arithmetically impossible.
5. est.ebitdaAvg and est.ebitAvg are fixed-ratio fabrications — REJECTED. ebitdaAvg is exactly 27.07% of revenueAvg and ebitAvg exactly 18.67% in every year FY2027 to FY2031. The EBITDA ratio happens to sit within 0.1 point of the actual fiscal 2026 margin of 27.0%, which makes it more dangerous than the obviously wrong cases elsewhere in this batch — a reader checking a single year would conclude it was sound.
6. est.epsAvg VALIDATES and carries the valuation. The FY2026 row of $5.518 against four reported adjusted quarters summing to $5.53 — a 0.2% difference. Coverage is 17 analysts on both FY2027 and FY2028 EPS with a 5.1% low-to-high dispersion on FY2028, which is unusually tight and is disclosed as a positive.
7. Fiscal-year-end dates are internally inconsistent between blocks — noted, immaterial. inc_a dates fiscal 2025 as 2025-04-30; bal_a dates the same year as 2025-04-25. The 10-K's fiscal 2026 year-end is 2026-04-24. A five-day discrepancy that affects nothing, but it is recorded because a 52/53-week retail-style calendar can distort growth rates and a reader should know the dating is loose.
8. Trailing GAAP EPS is far below trailing adjusted EPS — the gap is amortisation and it is large. Trailing GAAP diluted is $3.744 against a trailing adjusted total of $5.53 — a 47.7% gap, the widest in this batch after Starbucks. The driver is $2,958 million of depreciation and amortisation on a $52,733 million goodwill-and-intangible base. The trailing P/E of 23.1x and the adjusted 15.6x are both shown, and forward multiples use the adjusted basis to match the estimates. A reader should note that the amortisation being excluded is the accounting consequence of the acquisitions that produced the 6.13% return on invested capital.
Not defects, correctly reported and independently confirmed: seg_prod reconciles to reported revenue within 0.5% in every year shown and its division growth rates align with the 10-K's narrative; inc_q fourth-quarter revenue of $9,807M matches the earn_cal actual exactly; priceToBookRatioTTM of 2.23x is positive and economically meaningful — the only such book multiple in this batch; dividendPayoutRatioTTM of 75.8% is correct on GAAP earnings and corresponds to 67.1% on free cash flow; interestCoverageRatioTTM of 9.0x is consistent with the debt load; profile.currency is USD and inc_a[0].reportedCurrency is USD despite Irish domicile — no currency mixing; and earn_cal uses a consistent adjusted basis across all five reported rows, so the five-beat series is like-for-like.
8-K scan — completed. The three retained 8-Ks are 2026-04-27, 2026-05-18 and 2026-06-03, all short (3,460 to 7,080 characters) and prose-only. No corporate action postdating the 24 April 2026 balance sheet appears in them. The MiniMed initial public offering of 9 March 2026 was found in the 10-K, not the 8-Ks, because the announcing filings predate the three retained here.
Non-equity tripwire — checked and passed. MDT is ordinary shares of an Irish-domiciled plc, NYSE-listed. The $86.20 price is not par-like; beta is 0.583; the dividend is variable and has been raised for many consecutive years rather than fixed; volume was 5.96M shares (~$514M of turnover); and the 52-week band of $73.75 to $105.35 is a 43% range. This is common equity. Note that profile.country reads IE and profile.state reads GA — the latter is a mis-parse of Galway, Ireland as the US state of Georgia, which is cosmetic and affects nothing.
7. Technicals
- Price $86.20, down 0.55%. −18.2% from the 52-week high of $105.35; −36.2% from the six-year peak; +16.9% above the low of $73.75. Position within the annual range: 39.4th percentile.
- Moving averages, split: +6.2% above a rising 50-day of $81.14; −4.2% below a falling 200-day of $90.01. The intermediate trend has turned up; the long-term trend has not.
- RSI 69.7 — the highest reading in this batch and close to the conventional overbought threshold. MACD +1.43. Beta 0.583.
- Relative performance, with a clear turn: 3-month +10.1% vs SPY +7.6% — outperformance; 6-month −16.1% vs SPY +11.1% — a 27-point gap; 12-month −3.5% vs SPY +24.3% and QQQ +30.8%. A 27.8-point twelve-month underperformance, with the last three months positive.
- Sentiment, and it is the most one-sided in this batch: 1 strong buy, 30 buy, 20 hold, ZERO sell across 51 analysts. Consensus $95.57 (+10.9%), median $94, high $119 (+38.1%), low $80 — only 7.2% below spot.
What the technical picture does to the entry. The valuation case is strong and the timing is not ideal. RSI at 69.7 after a 10.1% three-month move means buying into a bounce, and the 200-day average at $90.01 is 4.2% overhead and still falling. Against that: the stock remains 36.2% below its multi-year peak, the lowest of 51 analyst targets is only 7.2% below the current price, and there are no sell ratings at all. The honest position is that the entry is not at the low, and that a base fair value 16.0% above spot with a 3.31% dividend does not require one.
8. Insiders
The insider block for Medtronic contains no transactions that support inference in the records available — reported as an absence of data.
Corporate capital behaviour is the substitute and it is the one weak signal in an otherwise constructive picture: buybacks fell from $3,235 million in fiscal 2025 to $1,035 million in fiscal 2026, a 68% reduction, while the dividend rose from $3,589M to $3,639M. A company trading at 14.5x forward earnings and 2.23x book that cut its buyback by two-thirds is either preserving cash for the MiniMed separation costs or is not confident in its own valuation. The 10-K names 'transaction, advisory, legal, accounting, information technology, separation and stand-up costs, and potential dis-synergies or stranded costs' as consequences of the separation, which is the more likely explanation — but it is worth watching whether the buyback returns.
9. Verdict, kill-criteria and flip conditions
Buy — Tactical.
The case, stated as arithmetic:
- Base fair value $100 against a $86.20 close — plus 16.0% — plus a 3.31% dividend for a total of 19.3%, against a bear case of $75, minus 13.0%. Asymmetry 3.46:1, the best in this batch.
- 14.5x the FY2027 consensus and 13.5x FY2028 on estimates carried by 17 analysts each with a 5.1% dispersion, for a company that grew revenue 8.4% last year — roughly half the multiple large-capitalisation device peers command.
- A growth acceleration with named product causes, not aggregate hand-waving: Cardiac Rhythm and Heart Failure +17% on pulsed-field ablation, Coronary and Peripheral Vascular +5% on Symplicity Spyral renal denervation, quarterly growth accelerating through the year to +9.9%, and five consecutive earnings beats.
- A portfolio simplification already executed: the MiniMed initial public offering of 9 March 2026, with the stated intention to dispose of the remaining ~90% — which removes the one business an independent knowledge-base claim says Medtronic cannot win.
- A 3.31% dividend covered at 67% of free cash flow, a 4.92% free-cash-flow yield, 2.23x book — the only positive and meaningful book multiple in this batch — 9.0x interest coverage, and beta 0.583.
- A street of 31 buy ratings, 20 holds and ZERO sells, with the LOWEST of 51 price targets only 7.2% below the current price.
What we are underwriting, and it is a real risk: a 6.13% return on invested capital — the lowest in this batch — produced by decades of acquisition that left $52,733 million of goodwill and intangibles on $93,028 million of assets. That is not a cyclical artefact; it is what Medtronic has been. We are not arguing it has changed. We are arguing that 14.5x forward earnings, 2.23x book and a 4.92% free-cash-flow yield is the price of a company that does not grow — and it grew 8.4%. Add to that: filings in this archive are prose-only, so no statement is filing-verified; seg_geo for fiscal 2026 is corrupt by $53 billion; consensus itself models the acceleration fading to 3.5% by fiscal 2028; RSI at 69.7 means buying after a 10% bounce; and the single knowledge-base claim naming this company is against it.
The reason this is Tactical rather than Core. One year of acceleration does not reverse a decade of capital allocation, and the confirmation is 28 days away. A Core position would require evidence that return on invested capital is moving, and there is none yet. What there is, is a valuation that assumes nothing improves, against a year in which several things demonstrably did.
Pre-registered KILL criteria — what would take this to Avoid:
- Cardiac Rhythm and Heart Failure growth falling below 8% in the 2026-09-01 print or thereafter, which would mark the pulsed-field cycle as already mature and remove the entire acceleration thesis.
- Total revenue growth reverting below 4%, back to the fiscal 2022-2025 pattern.
- Any impairment against the $52,733 million of goodwill and intangibles, which would convert the low return on capital from an operating fact into a balance-sheet event.
- The MiniMed separation stalling or being abandoned — the 10-K explicitly warns this is possible — which would remove the portfolio-simplification leg.
- Tariff and duty costs materially exceeding the $185 million of fiscal 2026 without offsetting price, compressing a gross margin that has not moved in five years.
- Return on invested capital falling below 5.5%.
Pre-registered SELL / trim conditions — what would take this back to Watch:
- Price above approximately $105 (16.4x FY2028E, 17.6x FY2027E) without a corresponding improvement in return on invested capital — the multiple would then have closed most of its peer discount on one year of evidence.
- Fiscal 2028 consensus revenue being revised DOWN, confirming the street's view that the acceleration was a one-year event.
- The buyback remaining below $1.5 billion a year after the MiniMed separation costs have passed, which would suggest capital discipline has not changed.
Pre-registered ADD conditions — what would take this toward Core:
- Return on invested capital sustained above 8%, which is the only thing that would justify a structural rather than cyclical re-rating.
- A completed MiniMed disposal with proceeds directed to buybacks or debt reduction rather than to further acquisition.
- Two more quarters of double-digit Cardiac Rhythm and Heart Failure growth, establishing pulsed-field ablation as a multi-year franchise rather than a launch effect.
Position sizing and where MDT fits in the Synthos Framework Portfolio. The medical-technology sleeve, at 2% today on this call, with a 3% target on confirmation from the 2026-09-01 print. Sized as Tactical rather than Core because the thesis rests on one year of data and because the filings could not be verified — a prose-only archive is a real reduction in confidence and is reflected in the sizing rather than ignored. Batch overlap note: Vertex (VRTX) is in this batch and appears in Medtronic's own vendor peer set, but they share only a healthcare sector code — Vertex is a discovery-led biotech with 85% single-product concentration and Medtronic a diversified device manufacturer with none. They are not the same exposure and both can be held. Logged as a tracked Synthos call (Buy — Tactical) as of 2026-08-04 at $86.20.
Single biggest risk: the 6.13% return on invested capital does not move, and the fiscal 2026 acceleration turns out to be a product cycle rather than a change in the company. Medtronic's low multiple is not an oversight — it is the market's considered judgement on thirty years of capital allocation that produced $52,733 million of goodwill and intangibles, 56.7% of assets, and a return on invested capital below its cost of capital. Pulsed-field ablation and renal denervation are genuine and they are also, in the end, two products. If Cardiac Rhythm and Heart Failure decelerates from 17% toward the mid single digits as competitors scale — and pulsed-field is not a Medtronic monopoly — total revenue growth returns to the 3.5% consensus already models for fiscal 2028, and 14.5x forward earnings turns out to have been the right price rather than a cheap one. The bear case of $75 is not a crash scenario; it is simply what happens if nothing has changed. We are paid 16% plus a 3.31% dividend to take that risk against a 13% downside, and the first confirmation arrives in 28 days.
Provenance & disclosures
- Traceability: EXACTLY ONE tagged knowledge-base claim names Medtronic, and it is a claim AGAINST the company — business_breakdowns, 2023-05-10, bullish at conviction 75 on entities Dexcom, DXCM, Abbott, ABT, Medtronic and MDT: "CGM is a stable duopoly of Dexcom and Abbott; competition is not a real risk because manufacturing accurate sensors is very hard." Medtronic appears as the excluded third party. The claim is corroborated by the company's own action — the MiniMed initial public offering of 9 March 2026 separating the Diabetes business — and both are reported. A supplementary sector sweep on Medtronic, medical device, pulsed field, renal denervation, continuous glucose, insulin pump and surgical robot returned 8 further text hits, none naming Medtronic, of which five are discarded: two lex_fridman claims on FDA rapid-test authorisation policy (the collision is on "medical device" as a regulatory classification), a david_sinclair claim on continuous glucose monitoring for non-diabetic longevity use, a raoul_pal claim about humanoid surgical robots in ten to fifteen years, and a 2023 sector-rotation observation. Three are usable and two are negative: a business_breakdowns claim (2023-05-10, conviction 70) that Dexcom's closed-loop ecosystem integration is the long-term value driver in diabetes, reinforcing the first claim from the competitor's side; and two claims from Dev Kantesaria (we_study_billionaires, 2021-10-22, the only NAMED independent speaker in the lane, conviction 70 and 65) stating that he avoids "biotech, pharma, medical devices and all healthcare because high R&D risk makes them not predictable enough for a five-to-ten-year path to organic growth and free cash flow" — a category-level avoidance from a named investor, recorded as a genuine negative. Net conviction is NEGATIVE-LOW, breadth 2, and this is the only name in this batch where the knowledge base reads negative while the verdict is positive — a divergence stated openly rather than resolved by ignoring the lane. The reconciliation is that the lane's substantive objection is to the Diabetes business, which Medtronic has now floated. All quotes are verbatim from the stored claim text.
- Data as-of: annual statements fiscal 2026 ended 2026-04-24 from
inc_a/bal_a/cf_a, with narrative corroboration from the 10-K filed 2026-06-18 (the MiniMed separation, division-level growth rates with product attribution, cost-of-products-sold and tariff detail) · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873602 = 2026-08-04T20:00:02Z ($86.20, −0.55%; 50-DMA $81.14; 200-DMA $90.01; RSI 69.7; MACD +1.43; beta 0.583) · knowledge-base claims 2026-08-04. Fiscal note: Medtronic's fiscal year ends in late April. "Fiscal 2026" means the year ended 2026-04-24, and the first quarter of fiscal 2027 is reported 2026-09-01. CRITICAL: no statement figure in this dive is filing-verified, because the filings in this archive are prose-only. All figures come from the Synthos vendor data file for MDT or from the SEC filings in the MDT archive; no figure comes from memory, recall or external retrieval. - Filing archive contents and its central limitation: 10-K filed 2026-06-18 (fiscal 2026); 10-Q filed 2025-11-25 (October 2025 quarter); 10-Q filed 2026-02-24 (January 2026 quarter); 8-K filed 2026-04-27; 8-K filed 2026-05-18; 8-K filed 2026-06-03 — all three 8-Ks short (3,460 to 7,080 characters) with no extracted exhibits. CRITICAL: a direct count returns ZERO
[TABLE]markers across the 10-K and both 10-Qs. Medtronic's filings in this archive are prose-only, and no income statement, balance sheet, cash-flow statement or segment table is recoverable. Narrative numbers were extracted and used extensively — the MiniMed initial public offering terms and retained ownership, the three-reportable-segment structure, division-level net sales growth with named product drivers (pulsed ablation, Micra, Aurora EV-ICD, Penditure, Avalus Ultra, VitalFlow, Symplicity Spyral, MiniMed 780G), cost of products sold of $12.7 billion against $11.6 billion, and the $185 million of increased tariffs and duties plus $84 million of asset write-offs. But the statements themselves are vendor-sourced and unverified, and the position is sized as Tactical partly for that reason. - Where the filings contradicted or corrected the vendor (detailed in Section 6):
seg_geofor fiscal 2026 rejected in full — it reports United States revenue of $71,397M and a three-region total of $89,658M for a company with $36,364M of revenue, a 147% overstatement and the largest absolute data error in this batch, while the fiscal 2025 and fiscal 2024 rows reconcile exactly; the Diabetes separation — MiniMed Group's initial public offering of 9 March 2026 with ~10% sold and ~90% retained, and Diabetes ceasing to be a reportable segment in Q4 FY2026 — appears in NO vendor field, whileseg_prodstill presents "Diabetes Group" as a fiscal 2026 segment;est.netIncomeAvgrejected for exceedingest.ebitAvgin FY2029, FY2030 and FY2031;est.ebitdaAvgandest.ebitAvgrejected as fixed-ratio fabrications at exactly 27.07% and 18.67% of revenue in every forward year — with the specific warning that the EBITDA ratio sits within 0.1 point of the true fiscal 2026 margin, making it harder to detect than the obviously wrong cases elsewhere in this batch; fiscal-year-end dates noted as internally inconsistent betweeninc_a(2025-04-30) andbal_a(2025-04-25); the 47.7% gap between trailing GAAP and adjusted EPS identified as amortisation on a $52,733M intangible base. Where vendor and filing AGREED — worth recording:seg_prodreconciles to reported revenue within 0.5% in every year and its division growth rates align with the 10-K's narrative;inc_qfourth-quarter revenue of $9,807M matches theearn_calactual exactly;est.epsAvgfor fiscal 2026 ($5.518) is within 0.2% of the four reported adjusted quarters ($5.53). The 8-K scan returned no corporate action postdating the 24 April 2026 balance sheet. - Basis note: analyst estimates and
earn_calactuals are adjusted (non-GAAP); reported diluted EPS is GAAP, and the gap is very wide — trailing adjusted EPS is $5.53 against trailing GAAP diluted of $3.744, a 47.7% difference driven by $2,958 million of depreciation and amortisation on a $52,733 million goodwill-and-intangible base. A reader should note explicitly that the amortisation being excluded from the multiple everyone quotes is the accounting consequence of the acquisitions that produced the 6.13% return on invested capital — this is the most important basis caveat on this name. Theearn_calbasis is consistent across all five reported rows, so the five-beat series (+2.5%, +2.4%, +3.8%, +1.5%, +0.6%) is like-for-like and shows a well-guided company with narrowing surprises. Forward multiples use consensus adjusted EPS; the trailing multiple is shown on both bases (15.6x adjusted, 23.1x GAAP diluted). - Estimate coverage: 21 analysts on fiscal 2027 and fiscal 2028 revenue and 17 on both EPS lines — among the best-covered pairs in this batch — falling to 12 and 6 for fiscal 2029, and 5-6 and 2-4 for fiscal 2030 and 2031, both of which are excluded from every conclusion. The fiscal 2028 EPS dispersion (low $6.257, mean $6.397, high $6.577 — a 5.1% low-to-high spread) is the tightest in this batch and is what a large, diversified, well-guided device company looks like. The fair-value anchors rest on that row.
- Peer note: the vendor peer set contains four genuine comparables — Boston Scientific, Edwards Lifesciences, Stryker and, from this batch, Vertex — alongside Bristol-Myers Squibb, CVS, GSK, HCA, McKesson and Sanofi, which are pharmaceutical, distribution or provider businesses rather than device manufacturers. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn — the statement that Medtronic trades at roughly half the device-peer multiple is a general observation and is labelled as such rather than presented as a computed figure from this file.
- Fair-value caveat: the $75 / $100 / $125 anchors are multiples of the fiscal 2028 consensus adjusted-EPS distribution — 12.0x the low of $6.257, 15.6x the mean of $6.397, and 19.0x the high of $6.577 — cross-checked against fiscal 2027E of $5.954. Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 14x gives $90 and 17x gives $109, and the current price of $86.20 sits BELOW the bottom of that band. The base assumes modest multiple EXPANSION from 14.5x to roughly 15.6x, and Section 4b flags that explicitly as the fragile leg — while also noting that a HELD multiple still gives $93 and a 10.7% total return with the dividend, so the re-rating is not required for the position to work. None of the anchors reflects the eventual MiniMed disposal, because its timing, structure and proceeds are undisclosed and the 10-K warns it may not occur at all.
- Timing: fiscal 2026 results were released 2026-06-03 and the 10-K filed 2026-06-18, both more than six weeks before this dive. The next print is 2026-09-01, 28 days away — the first quarter of fiscal 2027 and the first full period reported after the MiniMed initial public offering — with consensus adjusted EPS of $1.39 and revenue of $9,549.1M. The verdict is set with that proximity as an input, and the position is sized as Tactical partly because the first confirmation of the growth thesis arrives within a month. 2026-08-04 was a marginally negative day for the stock (−0.55%) in a broadly higher market; no company-specific news for that date appears in this file.
- Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
- Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
- Version: 2026-08-04-full.